Table II.

The percentage of patients who achieved the target haemoglobin concentration (110 g/l) and the mean haemoglobin concentration once target was achieved.

	ESA-naïve	Prior ESA-treated
	n = 144	n = 62
Patients eligible for target Hb analysis, n*	129	57
KM (95% CL) percentage who reached target Hb†	82% (70, 94)	55% (40, 70)
KM (95% CL) median time to achieve the target Hb, weeks	7 (5, 9)	24 (9, NE)
Patients eligible for mean Hb analysis after target achieved, n‡	105	31
Mean (SD) Hb concentration of maintenance, g/l	116 (8)	117 (8)
Median (Min, Max) Hb concentration of maintenance, g/l	117 (99, 133)	118 (101, 136)
Mean Hb category after achieving target, n (%)
Less than 110 g/l	25 (24)	8 (26)
110–130 g/l	75 (71)	22 (71)
Greater than 130 g/l	5 (5)	1 (3)

ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; KM, Kaplan–Meier; CL, confidence limits; Min, minimum; Max, maximum; NE, not estimable.

*Patients who had haemoglobin data either at baseline or after baseline were considered eligible except for those patients with baseline haemoglobin ≥110 g/l. Patients who had no haemoglobin data after baseline were counted as not having achieved the target level.

†Patients had to reach the target haemoglobin level (110 g/l) in the absence of a red blood cell transfusion within the preceding 28 d.

‡Patients who had baseline haemoglobin ≥110 g/l or who achieved the target haemoglobin concentration of 110 g/l were included.